Canada Pension Plan Investment Board
RAPP

Canada Pension Plan Investment Board’s Rapport Therapeutics RAPP Stock Holding History

Canada Pension Plan Investment Board’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,100
Closed -$276K – 2055
2025
Q4 		$276K Buy
+9,100
New +$252K ﹤0.01% 1546

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Canada Pension Plan Investment Board's RAPP Position: Q1 2026 in Review

Canada Pension Plan Investment Board sold out of Rapport Therapeutics (RAPP) in Q1 2026, closing a stake of 9,100 shares — an estimated $276K sold.

Canada Pension Plan Investment Board first reported a position in RAPP in Q4 2025 and held it in 1 quarter. The position peaked at $276K in Q4 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Canada Pension Plan Investment Board reported no remaining Rapport Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Canada Pension Plan Investment Board sold 9,100 Rapport Therapeutics shares in Q1 2026, an estimated $276K.
  • Canada Pension Plan Investment Board first reported a position in Rapport Therapeutics in Q4 2025 and held it in 1 quarter.
  • Canada Pension Plan Investment Board's Rapport Therapeutics position peaked at $276K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Canada Pension Plan Investment Board's 13F filing for Q1 2026, filed 15 May 2026.